Schizophrenia
Conditions
Keywords
Schizophrenia, NMDA receptor, D-serine, Recent onset, Negative symptoms, Cognition
Brief summary
The purpose of this study is to compare efficacy and safety of add-on treatment with a moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset schizophrenia patients who suffer from significant symptoms despite treatment with antipsychotics.
Detailed description
Background: Recent advances in understanding the neurobiology underlying schizophrenia have underscored a pivotal role for a specific receptor for the neurotransmitter glutamate, the NMDA receptor, whose function may be impaired in the disorder. Enhancing transmission at the NMDA receptor may therefore provide a novel mechanism for treating schizophrenia. Over the past decade clinical trials that included supplementation with different compounds enhancing transmission at the NMDA receptor have provided positive results, particularly with D-serine. However, none of these trials focused specifically on young patients with recent onset schizophrenia. In addition, the optimal D-serine dose was not determined, although a preliminary report suggested that higher doses than those used in most studies may provide additional benefit, without significant safety concerns or side effects. Also, the pro-cognitive effects of D-serine were not systematically analyzed, although preliminary data supports a potential role for D-serine in ameliorating the cognitive deficits found in schizophrenia. Research Design: Over a two year period, 54 patients, male or female, aged 18-30 years who fulfill DSM-IV criteria for schizophrenia or schizoaffective disorder, will be entered into a 12 week, parallel group, double blind, randomized controlled trial assessing the efficacy of placebo vs. DSR (up to 6000 mg/day) augmentation to standard antipsychotic therapy. First episode patients, and patients treated with clozapine, will be randomized separately. Patients will be entered into the trial in accordance with strict inclusion and exclusion criteria after the nature of the study has been explained to them and they have given written informed consent. Clinical evaluations will be performed at baseline and then at regular intervals during the trial. In addition, neurocognitive evaluations, electrophysiological assessments and determination of amino acids levels will be conducted at the beginning and end of the study. Treatment emergent adverse effects will be monitored.
Interventions
DRUGD-serine
Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Sponsors
Herzog Hospital
Hadassah Medical Organization
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-30 * Diagnosis of schizophrenia/schizoaffective disorder * Recent onset (up to five years since onset of positive symptoms) * Stable dose antipsychotic treatment for at least 4 weeks * Baseline PANSS total score of at least 70 * Baseline PANSS negative subscale score of at least 20 * Clinically stable (stable CGI score for two consecutive weeks)
Exclusion criteria
* Criteria for other DSM-IV Axis I diagnoses are met * Lifetime history of alcohol or substance dependence * Alcohol or substance abuse within the past year * Judged clinically to be at suicidal or homicidal risk * Female patients who are pregnant or lactating. * Patients with known intolerance to D-serine treatment * Patients treated with ECT within 12 weeks prior to study entry * Patients treated with TMS within 4 weeks prior to study entry * Patients suffering from an unstable and/or untreated medical disorder * Patients suffering from renal or hepatic dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in the Total Score of the Positive and Negative Syndrome Scale (PANSS) | Biweekly for 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in the Subscales of PANSS | Biweekly for 12 weeks | — |
| Change from Baseline in the Clinical Global Impressions (CGI) | Biweekly for 12 weeks | — |
| Change from Baseline in the Scale for the Assessment of Negative Symptoms (SANS) | Biweekly for 12 weeks | — |
| Change from Baseline in the Calgary Depression Scale for Schizophrenia (CDSS | Biweekly for 12 weeks | — |
| Change from Baseline in the Quality of Life Scale (QOL) | Biweekly for 12 weeks | — |
| Change from Baseline in the Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery | 12 weeks | — |
| Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) | Biweekly for 12 weeks | — |
| Change from Baseline in the Udvalg for Kliniske Undersgelser (UKU) Side Effect Rating Scale | Biweekly for 12 weeks | — |
| Change from Baseline in the Prepulse Inhibition (PPI) of Startle | 12 weeks | Patients with schizophrenia and their relatives may exhibit deficits in this operational measure of sensorimotor gating |
| Amino Acid Serum Levels | 12 weeks | Glutamate, Glycine, D-serine |
| Change from Baseline in the Simpson-Angus Extrapyramidal Rating Scale (SAS) | Biweekly for 12 weeks | — |
Countries
Israel
Contacts
Primary ContactAmit Lotan, MD
Backup ContactBernard Lerer, MD
Outcome results
None listed